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RESUMO – O eritema acral da quimioterapia é caracterizado por áreas eritematosas e dolorosas, envolvendo predominantemente 
as mãos e pés, com formação de bolhas em casos severos. A gemcitabina é responsável frequentemente por reacções adversas 
cutâneas, embora estas sejam habitualmente transitórias e ligeiras. Relatamos o caso de um doente sob quimioterapia paliativa com 
gemcitabina por adenocarcinoma ductal pancreático, que desenvolveu lesões bolhosas em ambos os pés, de maiores dimensões à 
esquerda. A histopatologia foi consistente com eritema acral. A variante bolhosa do eritema acral da quimioterapia é uma reacção 
rara e, embora descrita para agentes citotóxicos estruturalmente semelhantes, não tem sido associada à gemcitabina. No doente 
apresentado, os antecedentes pessoais de doença arterial periférica podem ter desempenhado um papel importante na apresenta-
ção clínica final. 
PALAVRAS-CHAVE – Dermatopatias Vesiculobolhosas/induzido quimicamente; Dermatoses do Pé/induzido quimicamente; Erite-
ma/induzido quimicamente; Gemcitabina/efeitos adversos.
Gemcitabine-Induced Bullous Acral Erythema 
ABSTRACT – Chemotherapy-induced acral erythema is characterized by areas of painful erythema affecting predominantly hands and 
feet, and in severe cases bullous lesions may develop. Gemcitabine is frequently responsible for cutaneous side effects, but these are 
usually mild and transient. We report a patient under palliative chemotherapy for pancreatic ductal adenocarcinoma with gemcitabi-
ne, who presented large bullous lesions on both feet, but of larger size on the left. Histopathology was consistent with acral erythema. 
The bullous variant of chemotherapy-induced acral eythema is a rare reaction, and although described for structurally similar cytotoxic 
agents, it has not been reported in association with gemcitabine. In our case, the patient’s medical history of significant peripheral 
arterial disease may have also played an important role in the overall clinical presentation.
KEY-WORDS – Erythema/chemically induced; Foot Dermatoses/chemically induced; Gemcitabine/adverse effects; Skin Diseases, 
Vesiculobullous/chemically induced. 
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INTRODUCTION
Chemotherapeutic agents are responsible for numerous 
well described adverse reactions that may affect the skin, 
hair, mucous membranes and nails. Chemotherapy-induced 
acral erythema is a dose-dependent response to numerous 
cytotoxic agents characterized by painful well-demarcated 
erythematous plaques, affecting predominantly palms and 
soles. In severe cases, diffuse or focal blistering with possible 
ulceration may occur.
Gemcitabine is a nucleoside analogue with demonstrated 
206
Caso Clínico
efficacy across a range of solid tumors and has a mild toxicity 
profile. Cutaneous side effects are frequent, but the bullous 
variant of acral erythema has not yet been attributed to ge-
mcitabine.
CASE REPORT
We report the case of a 47 year-old male, under palliati-
ve chemotherapy for pancreatic ductal adenocarcinoma. His 
past medical history was remarkable for insulin-dependent 
diabetes mellitus and for peripheral arterial disease, with an 
aortobifemoral bypass that had already been complicated 
with thrombosis of the left branch.  At the time of presentation, 
he was in the second cycle of gemcitabine (1000mg/m2), and 
had previously undergone four cycles of gemcitabine + ca-
pecitabine. Dermatology observation was requested for a 24-
hour history of dysesthesia and bullous lesions on both feet, of 
larger size on the left foot, two days after the last chemothera-
py session. These bullous lesions were tense, up to 30-70mm 
in diameter, had a citrus content and a violaceous base, with 
whitish and erythematous concentric halos (Fig. 1).
The patient had no other cutaneous lesions, no periphe-
ral oedema, and no other abnormalities were noticed in the 
physical examination. There was no prior history of trauma 
or tissue injury.
Complete blood count showed haemoglobin of 11.5 gr/
dL, leucocytes 5.3x109/L (57% of neutrophils) and thrombo-
cythopenia with platelets 82x109/L. Biochemistry panel re-
vealed C-reactive protein 3.5mg/dL, creatinine 0.75 mg/
dL, HbA1c 9.8% with no other particular abnormalities. Anti-
-nuclear antibodies and anti-neutrophil cytoplasmatic anti-
bodies were negative.
Cultures of blood, urine and exudate from bulla were ne-
gative.
Biopsy of a bullous lesion revealed necrosis of the super-
ficial layers of the epidermis, single apoptotic keratinocytes 
in the lower layers, and formation of small multifocal intrae-
pidermal or subepidermal vesicles. On the upper dermis, 
congested and thrombosed capillaries were seen. Eccrine 
glands were hyalinized and distorted, suggesting necrosis. 
The inflammatory infiltrate was mild, consisting predominan-
tly of sparse interstitial neutrophils. These features were hi-
ghly suggestive of a reaction to chemotherapy, conforming to 
the bullous variant of acral erythema (Fig. 2).
After a slight improvement with high potency topical cor-
ticosteroids, there was clear worsening after a new gemcita-
bine infusion 12 days after the previous administration, with 
ulceration and necrotic eschars in the previously affected lo-
cations (Fig. 3a).
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Figure 1 - Large bullous lesions on the left foot, 2 days after second cycle of gemcitabine (A). Smaller bullous lesions on the right foot (B). Detail of a 




Figure 2 - Dyskeratotic keratinocytes in the upper layers of the epidermis, subepidermal vesiculation and congested capillaries (A). Paleness and hyali-




The anti-neoplastic treatments were suspended for 49 
days, leading to a significant improvement of the ulcerations.
Although there was a possibility of clinical worsening, con-
sidering the benefits of continuing with chemotherapy, the pa-
tient was started again on gemcitabine maintaining the same 
dose (1000 mg/m2) and without any kind of pre-medication. 
He concluded the 4th and 5th cycle of his chemotherapy, and 
kept a good evolution with proper wound care, which culmina-
ted in complete ulcer healing approximately 4 months after the 
initial presentation (Fig. 3b).
DISCUSSION
We report a case of acral erythema induced by gemcita-
bine, with a striking presentation consisting of large bullous 
lesions associated with dysesthesia. The Naranjo probability 
score1 showed a probable relationship between gemcitabine 
and the cutaneous lesions (calculated score = 6), and this hy-
pothesis was strongly supported by the histopathology. Other 
differential diagnosis like auto-immune diseases or acral vas-
culitis were considered less probable. Regarding auto-immune 
diseases there was no background, additional cutaneous or 
systemic manifestations, as well as no serologic data in favor 
of this hypothesis. Considering acral vasculitis (paraneoplastic 
syndrome), there was no Raynaud phenomenon or other signs 
of ischemia (acrocyanosis, digital gangrene or pain) that are 
usually associated. Improvement is frequently only seen after 
control of the primary disease,2 which was not the case in our 
patient. The histopathology was also not in favor of these diag-
nosis has it showed only thrombosed capillaries, with no signs 
of vasculitis, namely fibrinoid necrosis, perivascular inflamma-
tory infiltrate or karyorrhexis.
Acral erythema is a common adverse reaction to 
chemotherapy, but is still a matter of some confusion for cli-
nicians. The heterogeneous clinical presentations due to the 
various grades of severity3 and sites involved, in addition to 
the different histologic findings (some more prominent in ec-
crine glands, while others more pronounced in the epidermis), 
may explain its numerous designations in the literature (e.g. 
hand-foot syndrome, Burgdorf reaction, eccrine squamous 
syringometaplasia, epidermal dysmaturation, palmoplantar 
erythrodysestesia and neutrophilic eccrine hidradenitis). More 
recently the designation toxic erythema of chemotherapy was 
proposed as an encompassing term.4,5
Typically the full blown picture develops after several cycles 
of chemotherapy but the clinical course is difficult to predict as 
it may worsen from cycle to cycle, while others may heal du-
ring therapy-free intervals, and some may even tolerate further 
treatments without any recurrence.6
The severe bullous variant of chemotherapy-induced acral 
erythema is a rare reaction, and although described for struc-
turally similar cytotoxic agents like cytarabine,7 it has not been 
reported in association with gemcitabine. Other agents in rela-
tion with this variant include methotrexate, cyclophosphamide 
and vincristine.8
With the introduction of new targeted cancer therapies, se-
veral new cutaneous drug reactions have been described. The 
hand-foot-skin reaction has been described in association with 
the multikinase inhibitors (sorafenib and sunitinib) and has si-
milarities with acral erythema from conventional chemothera-
py, but is distinguished clinically by localized lesions (instead of 
diffuse involvement), particularly in friction areas, that rapidly 
become hyperkeratosic.9,10
Gemcitabine’s cutaneous toxicity is reported in 24.8% of 
patients,11 predominantly maculopapular rash, alopecia and 
mucositis, which are usually mild and transient. However there 
are also several adverse reactions that have been seldom re-
ported, including entities within the spectrum of acral erythe-
ma, such as fixed erythrodysaethesia12 and recurrent toxic 
erythema.13
Recently some authors14,15 reported on gemcitabine-indu-
ced bullous lesions, although apparently not in the context of 
acral erythema. In both cases, the histopathology did not show 
any aspects suggestive of a toxic reaction.
The pathomechanism of acral erythema is not completely 
elucidated, but histological investigations suggest a toxic effect 
on the basal keratinocytes and upper dermal vessels.16 In our 
case the underlying vascular disease may have also played 
an important role in the overall clinical presentation. Accor-
ding to some authors,17 gemcitabine-induced reactions may 
be caused by accumulation of the drug in the skin and sub-
cutaneous tissue, and since this type of reaction seems to be 
dose-dependent, the vasculopathy could have increased local 
toxicity. In this sense, we speculate that the suspension of the 
drug may have permitted the elimination of the drug and its 
metabolites leading to improvement of the lesions, while the 
later reintroduction did not originate enough local toxicity to 
cause clinical worsening.
Gemcitabine was also associated with cases of vascular 
toxicity, namely necrotizing vasculitis and digital ischemia.18,19 
Therefore it is recommended caution while using gemcita-
bine in patients with micro or macroangiopathy and with 
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Figure 3 - Necrotic eschars after the third cycle of gemcitabine (A). 





auto-immune diseases, since the risk of digital necrosis is hi-
gher in these cases.20 Additionally, according to some authors, 
it is also possible that vascular aggression plays a part in acral 
erythema, and in fact we cannot exclude a contribution of the 
vascular thrombosis observed in our case, but the overall pre-
sentation is considered to result most likely from the epidermal 
insult by the gemcitabine.13
In the management of acral erythema, dose modification, 
systemic or local symptomatic approaches can be used.21 Dose 
reduction or interruption of the therapy is often necessary ini-
tially, and if acral erythema repeatedly recurs even more se-
verely, dose adjustment or discontinuation of therapy may be 
inevitable. Pyridoxine has also been found beneficial and high-
-potency corticosteroids have been proven effective as topical 
therapy.16 The use of pre-medication with dexamethasone, be-
fore gemcitabine administration was also described in the lite-
rature, although mainly in the context of gemcitabine-induced 
maculopapular exanthema.22
As in our case, strict cooperation between dermatologist 
and oncologist is advisable, in order to wage the benefits and 
counterparts of suspending the chemotherapy.
We presented an impressive gemcitabine-induced case of 
acral erythema with bullous lesions, in which the severity and 
asymmetry were possibly due to the patient’s history of signifi-
cant peripheral arterial disease.
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